Novo Nordisk A/S Vállalati érték
Mi az Novo Nordisk A/S Vállalati érték?
A Vállalati érték az Novo Nordisk A/S - $292.82B
Mi a Vállalati érték meghatározása?
A vállalati érték a vállalat teljes piaci értékének mértéke. A piaci kapitalizáció az adósság, a kisebbségi részesedés és a preferált részvények összege, a pénzeszközök és pénzeszköz-egyenértékek összege mínusz.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Vállalati érték a Health Care szektor a OTC-on cégekben a Novo Nordisk A/S -hoz képest
Mit csinál Novo Nordisk A/S?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
vállalati érték -hoz hasonló cégek Novo Nordisk A/S
- Comcast Corp nak Vállalati érték $282.58B van
- Chevron nak Vállalati érték $284.95B van
- Roche AG nak Vállalati érték $287.91B van
- Coca-Cola Co nak Vállalati érték $290.54B van
- Astrazeneca plc nak Vállalati érték $291.74B van
- Merck & Co nak Vállalati érték $292.45B van
- Novo Nordisk A/S nak Vállalati érték $292.82B van
- Roche AG nak Vállalati érték $293.24B van
- Facebook nak Vállalati érték $297.82B van
- Bank Of America nak Vállalati érték $300.68B van
- Nestlé SA nak Vállalati érték $302.61B van
- Netflix nak Vállalati érték $315.31B van
- Verizon Communications Inc nak Vállalati érték $319.65B van